SCHEMBL29709490

SCHEMBL29709490

COc1ccc(Cn2ccc(C(=O)O)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.52
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 2/20 0.51
POLB P06746 1/20 0.51
PLA2G4A P47712 1/20 0.47
CMA1 P23946 1/20 0.46
PLA2G4B P0C869 1/20 0.46
CDK5 Q00535 1/20 0.45
CDK5R1 Q15078 1/20 0.45
CHRM1 P11229 2/20 0.45
LDHA P00338 1/20 0.45
HSP90AA1 P07900 1/20 0.45
ALKBH1 Q13686 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
TSHR P16473 1/20 0.44
TAS2R14 Q9NYV8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28321315 0.87 CA1 (0.53) CYP19A1CA1CA2CMA1CDK5
SCHEMBL7189635 0.84 ERCC5 (0.50) CYP19A1CMA1CDK5CDK5R1KMT2A
SCHEMBL27947884 0.83 SMN1; SMN2 (0.47) CYP19A1SMN1; SMN2POLBPLA2G4ATP53
SCHEMBL4671523 0.83 CYP19A1 (0.45) CYP19A1RAB9ASMN1; SMN2NPC1POLB
SCHEMBL4671526 0.83 CYP19A1 (0.45) CYP19A1RAB9ASMN1; SMN2NPC1POLB
SCHEMBL2514239 0.80 CYP2C19 (0.55) CYP19A1CA1CA2POLBTSHR
SCHEMBL2456750 0.77 BRD4 (0.53) CA1CA2RAB9ASMN1; SMN2NPC1
SCHEMBL27860133 0.77 TPMT (0.44) CYP19A1SMN1; SMN2POLBPLA2G4ATP53
SCHEMBL28102787 0.75 ALDH1A1 (0.45) CYP19A1RAB9ASMN1; SMN2NPC1CMA1
SCHEMBL10590280 0.74 TSHR (0.50) CA1CA2RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4008328-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS AbbVie Inc. (US) 2022-06-08 EP disclosed